KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 112 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q4 2020. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,154,115 | +23.4% | 66,443 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $935,517 | +30.9% | 66,443 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $714,927 | -28.2% | 66,443 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $995,316 | -0.3% | 66,443 | -14.5% | 0.00% | 0.0% |
| Q3 2022 | $998,000 | +102.8% | 77,753 | +53.1% | 0.00% | +100.0% |
| Q2 2022 | $492,000 | -6.1% | 50,794 | -3.7% | 0.00% | 0.0% |
| Q1 2022 | $524,000 | -15.6% | 52,740 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $621,000 | -26.2% | 52,740 | -28.5% | 0.00% | -50.0% |
| Q3 2021 | $841,000 | +13.6% | 73,813 | +38.9% | 0.00% | +100.0% |
| Q2 2021 | $740,000 | -24.7% | 53,125 | 0.0% | 0.00% | -50.0% |
| Q1 2021 | $983,000 | +4.7% | 53,125 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $939,000 | +133.6% | 53,125 | +102.7% | 0.00% | +100.0% |
| Q3 2020 | $402,000 | +88.7% | 26,209 | +213.8% | 0.00% | 0.0% |
| Q2 2020 | $213,000 | – | 8,352 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 2,374,392 | $36,376,000 | 4.43% |
| Opaleye Management Inc. | 338,000 | $8,778,000 | 1.72% |
| Lion Point Capital, LP | 495,748 | $7,594,000 | 1.67% |
| Fairmount Funds Management LLC | 212,746 | $3,259,000 | 1.38% |
| Vivo Capital, LLC | 1,151,622 | $17,643,000 | 1.02% |
| Spearhead Capital Advisors, LLC | 270,117 | $4,138,000 | 0.79% |
| Integral Health Asset Management, LLC | 120,000 | $1,838,000 | 0.56% |
| Endurant Capital Management LP | 117,480 | $1,800,000 | 0.53% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,990 | $3,983,000 | 0.39% |
| Ikarian Capital, LLC | 342,998 | $5,254,000 | 0.38% |